ANN ARBOR, MI – A groundbreaking study from the University of Michigan Health has cast a revealing light on the complex relationship between commonly used psychoactive substances and symptom management in individuals living with multiple sclerosis (MS). The research, published in the Archive of Physical Medicine and Rehabilitation, indicates that while many people with MS turn to substances like caffeine, alcohol, nicotine, cannabis, and opioids for immediate relief from debilitating symptoms, these quick fixes often come with a hidden cost, potentially exacerbating other symptoms such as fatigue, stress, or depressive states in the longer term.
The study’s findings underscore a critical paradox: the very substances sought for comfort or functional enhancement can inadvertently contribute to a cycle of symptom fluctuation, offering a temporary reprieve while subtly undermining overall well-being. This real-time investigation provides crucial empirical data, moving beyond anecdotal accounts to offer a more nuanced understanding of how daily substance use truly impacts the lives of those navigating the challenges of MS.
"Just as many people look to a cup of coffee in the afternoon for a pick-me-up, people with multiple sclerosis may seek caffeine to help with fatigue or alcohol to manage pain," explained Dr. Anna Kratz, a professor of Physical Medicine and Rehabilitation at University of Michigan Health and head of the Kratz Lab, who led the research team. "Insights from studies like this could prompt a person with multiple sclerosis to reflect on what they are putting into their bodies and how it is impacting their symptoms."
This research marks a significant step forward in understanding the intricate daily experiences of MS patients, offering a foundation for more informed patient discussions and personalized clinical guidance regarding the use of psychoactive substances.
The Daily Battle: A Chronology of Symptom Management in MS
Multiple Sclerosis is a chronic, often unpredictable disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Its manifestation is highly individual, presenting a diverse array of symptoms that can range from mild to severely debilitating. Fatigue, chronic pain, muscle spasticity, cognitive impairment, depression, anxiety, and sleep disturbances are just a few of the relentless challenges that individuals with MS often confront daily. The unpredictable nature of these symptoms, coupled with their waxing and waning intensity, often drives patients to seek immediate, accessible forms of relief.
Historically, symptom management in MS has focused on pharmaceutical interventions, physical therapy, and lifestyle modifications. However, the efficacy of these traditional approaches can vary, and many come with their own set of side effects. This often leads patients down a path of self-experimentation, exploring a wide range of substances – both prescribed and non-prescribed, legal and illicit – in an attempt to regain some control over their bodies and their lives. The use of psychoactive substances, whether for recreational purposes, social engagement, or specifically for symptom relief, is a pervasive aspect of modern society, and individuals with chronic conditions like MS are no exception. For many, a cup of coffee is an automatic response to morning fatigue, a glass of wine to unwind from pain, or cannabis to alleviate spasticity or neuropathic discomfort.
The challenge for both patients and clinicians has been the lack of robust, real-time data to truly understand the immediate and lingering effects of these substances on MS symptoms. Much of the previous understanding was based on retrospective self-reporting, which is prone to recall bias, or broad surveys that might miss the subtle, day-to-day fluctuations in symptom severity and substance impact. There was a critical gap in understanding the temporal associations – how a substance used at one moment might influence symptoms hours later or even the next day.
Recognizing this gap, Dr. Kratz and her team embarked on an ambitious study utilizing an innovative methodology known as Ecological Momentary Assessment (EMA). This approach is specifically designed to capture data in real-time, within the natural environments of participants, minimizing recall bias and providing a granular view of daily experiences. For 14 consecutive days, participants with MS were prompted four times a day to report on their current symptom severity across key domains: fatigue, pain, stress, and depressive symptoms. Crucially, they also reported whether they had used any of five commonly consumed psychoactive substances – alcohol, caffeine, nicotine, cannabis, or opioids – prior to their symptom ratings.
This rigorous data collection method allowed the research team to build a comprehensive picture of how substance use dynamically interacts with symptom presentation throughout the day, providing an unprecedented level of detail into these complex relationships. The study’s design was meticulously crafted to observe these patterns as they unfolded, offering a more accurate and ecologically valid understanding of the lived experience of MS and self-medication strategies.
The Data Speaks: Mixed Effects Unveiled
The detailed analysis of the real-time data revealed a consistent, albeit complex, pattern: the relief offered by psychoactive substances was frequently transient, often giving way to a rebound effect or exacerbating other symptoms. This "mixed effects" finding challenges the simplistic notion that these substances provide unmitigated benefits for symptom management.
The research team, which included Jeeyeon Kim from the University of Michigan, Dawn M. Ehde and Kevin N. Alschuler from the University of Washington, and Nora E. Fritz from Wayne State University, meticulously examined the correlations for each substance:
-
Caffeine: The ubiquitous morning ritual for many, caffeine is often consumed by individuals with MS to combat the profound fatigue characteristic of the condition. The study found that caffeine did indeed offer a short-term boost in alertness and a perceived reduction in fatigue. However, this temporary energy surge was often followed by an increase in anxiety or sleep disturbances later in the day. Poor sleep, in turn, is a significant contributor to worsened fatigue, creating a self-perpetuating cycle where the solution becomes part of the problem. Some participants reported increased jitters or exacerbation of stress symptoms after caffeine consumption, particularly if already feeling overwhelmed.
-
Alcohol: Often used as a social lubricant or a means to relax and manage pain, alcohol showed a similarly intricate profile. Immediate pain relief and a sense of relaxation were frequently reported. Yet, the data also indicated that alcohol consumption was associated with subsequent increases in fatigue, depressive symptoms, and even rebound pain. Alcohol can disrupt sleep architecture, leading to non-restorative sleep and consequently, heightened fatigue the following day. Its depressant effects can also deepen feelings of sadness or hopelessness in those already struggling with depression, a common comorbidity in MS.
-
Nicotine: While less directly associated with MS symptom management than other substances, nicotine use is prevalent, often linked to stress reduction or concentration enhancement. The study observed that while some participants reported a transient calming effect, nicotine use was often followed by increased stress and anxiety levels as the effects wore off or during withdrawal periods. Furthermore, the long-term health risks associated with nicotine, particularly for individuals with a chronic condition, remain a significant concern, potentially compounding other health challenges.
-
Cannabis: With increasing legalization and medical recognition, cannabis has emerged as a popular option for managing MS symptoms such as neuropathic pain, spasticity, and even sleep disturbances. The study’s real-time data affirmed that cannabis could provide immediate relief for pain and spasticity in many users. However, it also highlighted a potential for increased fatigue, cognitive impairment (often described as "brain fog"), and, in some instances, heightened anxiety or depressive symptoms in the hours following use. The psychoactive components of cannabis can vary widely, and different strains or consumption methods might yield different effects, making personalized guidance particularly critical.
-
Opioids: For individuals experiencing severe chronic pain, opioids are sometimes prescribed. The study confirmed their immediate efficacy in reducing pain levels. However, the data also pointed to the well-documented risks associated with opioids, including significant fatigue, constipation, and cognitive impairment. Moreover, the potential for dependence and the risk of hyperalgesia (increased sensitivity to pain over time) underscore the need for extreme caution and rigorous oversight in their use, particularly given the chronic nature of MS pain.
The overarching theme emerging from these findings is the sophisticated interplay between psychological expectation, physiological response, and the temporal dynamics of symptom presentation. Patients often seek immediate gratification – a quick fix – but the body’s compensatory mechanisms and the pharmacology of these substances mean that short-term gains can often translate into longer-term detriments, creating a challenging cycle of reliance. The study’s use of EMA allowed researchers to capture these subtle, yet significant, temporal associations that retrospective studies would likely miss.
Expert Commentary and Official Responses
Dr. Kratz emphasizes that these findings are not meant to condemn patients for their choices, but rather to empower them with a clearer understanding of the potential consequences. "Patients using psychoactive substances is not going to go away," she stated. "Being able to understand the role these substances play and the pros and cons of each will allow providers to better advise their patients when it comes to use of these products."
This sentiment forms the cornerstone of the study’s implications for clinical practice: fostering open, non-judgmental dialogue between patients and their healthcare providers. For too long, conversations about recreational or self-prescribed substance use have been shrouded in stigma, leading patients to withhold vital information from their care teams. The research advocates for a shift towards a more transparent and collaborative approach.
"Kratz not only encourages patients to talk with their provider about what outside psychoactive substances they are using habitually or for recreation or symptom management, but for providers to be attentive listeners as well," the study’s summary highlights. This "attentive listening" is crucial for providers to grasp the full spectrum of their patients’ self-management strategies and to tailor advice that is both empathetic and evidence-based. Understanding the patient’s motivations for using these substances – whether it’s the desperation for pain relief, the struggle against overwhelming fatigue, or the desire for social engagement – is key to offering practical, sustainable alternatives or modifications.
The study serves as a powerful reminder that healthcare providers need to actively inquire about all substances their patients might be using, beyond just prescribed medications. This includes caffeine intake, alcohol consumption, nicotine use, and any form of cannabis or opioid use, whether prescribed, over-the-counter, or from other sources. Equipped with this comprehensive information, providers can then engage in shared decision-making, helping patients weigh the immediate perceived benefits against the potential for long-term negative impacts on their overall MS management. This might involve suggesting alternative therapies, adjusting medication regimens, or recommending behavioral interventions that address the root causes of symptoms rather than merely masking them.
Broader Implications: A Path Towards Holistic MS Care
The implications of this study extend far beyond the immediate findings on individual substances. It represents a significant stride towards a more holistic, patient-centered approach to managing Multiple Sclerosis.
For Patients: This research empowers individuals with MS to become more discerning consumers of relief. By understanding the potential trade-offs, patients can make more informed choices about what they put into their bodies. It encourages self-reflection and perhaps even personal "ecological momentary assessment" – becoming more attuned to their own symptom fluctuations in relation to their substance use. This increased self-awareness can foster a proactive approach to managing their condition, moving away from reactive, temporary fixes towards sustainable well-being strategies. It also provides a scientific basis for open communication with their doctors, fostering a partnership built on trust and shared understanding.
For Healthcare Providers: The study provides empirical evidence to inform clinical guidance, moving beyond assumptions or anecdotal reports. It highlights the necessity for comprehensive screening and education regarding all forms of psychoactive substance use. This data can facilitate the development of more tailored symptom management plans that consider the complex interplay between different substances and various MS symptoms. It emphasizes the need for a patient-centered communication style, where providers acknowledge the patient’s attempts at self-management and guide them towards safer, more effective alternatives or strategies for substance use reduction.
For Researchers and Policymakers: The findings underscore the critical need for further research into specific dosages, strains (for cannabis), and long-term effects of these substances in the MS population. It could also spur the development of new, targeted therapies that address MS symptoms without the adverse rebound effects observed with commonly used psychoactive substances. Policymakers may use this data to inform public health campaigns, develop clearer guidelines for medical cannabis use in MS, and ensure that support systems are in place for individuals seeking to reduce or modify their substance intake. The study also serves as a model for using real-time data collection in chronic disease management, potentially influencing research methodologies across other complex conditions.
Ultimately, the University of Michigan Health study offers a pivotal understanding of the intricate dance between self-medication and symptom experience in MS. It reminds us that while the immediate allure of relief is powerful, true well-being in the face of a chronic condition demands a deeper understanding of cause and effect. By fostering open dialogue, promoting self-awareness, and equipping both patients and providers with robust data, this research paves the way for more effective, sustainable, and compassionate MS care, guiding individuals toward lasting comfort rather than fleeting respite.
Additional authors: Jeeyeon Kim, from the Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI. Dawn M. Ehde, from the Department of Rehabilitation, University of Washington, Seattle, WA. Kevin N. Alschuler, from the Department of Rehabilitation Medicine University of Washington, Seattle, WA and the Department of Neurology, University of Washington, Seattle, WA. Nora E. Fritz, from the Department of Health Care Sciences, Wayne State University, Detroit, MI and the Department of Neurology, Wayne State University, Detroit, MI.
Paper Cited: “Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis,” Archive of Physical Medicine and Rehabilitation. DOI: 10.1016/j.apmr.2026.01.014
